ベインのウェブサイトは、ユーザーの、利便性の向上、と機能改善のために、クッキーを使用しています。詳細は、弊社のプライバシーポリシーをご参照ください。このサイト閲覧を継続されることで、クッキーの使用についてご了承いただいたことになります。

スナップチャート

Blockbuster Drugs and New Tech Will Stoke the US Pharma Profit Pool

The expected growth in pharma revenues will expand the sector’s profit pool by 35% to $170 billion by 2024.

スナップチャート

Blockbuster Drugs and New Tech Will Stoke the US Pharma Profit Pool
en

Blockbuster drugs and new technologies such as cell therapy will increase pharma revenues and expand the sector’s profit pool by 35% to $170 billion by 2024. With an overall 26% operating margin, pharma continues to be one of the most profitable healthcare sectors. Through 2024, margins are expected to stay flat for branded drugs (34%) and over-the-counter products (19%). Lower prices and competition will shrink the profit pool for generic drugs. Pharma services are likely to see margins rise to 17%, up from 14%. Several key trends affecting pharma profits:

  • Specialty medicines will power revenue growth, with R&D focused on three high-value areas: oncology, rare diseases and neurology.
  • The market for gene and cell therapies could double to $2 billion by 2024, but as these therapies cure patients, profit pools may start to shrink.
  • Expiring patents will erode branded drug sales. By 2023, 18 of the current top 20 branded drugs will be facing generic or biosimilar competition.
  • Generics continue to take market share from branded drugs, but the rate of substitution is likely to plateau in the US, as 90% of US prescriptions already are generic.

Jason Evers and George Eliades are partners in Bain’s Healthcare practice. Jason is based in the firm’s Chicago office and George is located in the San Francisco office.

Read More

Healthcare Insights

Bain Insights dig deep into the complex challenges that healthcare companies—including hospitals, insurers and medtech firms—face in patient care.

Tags

お気軽にご連絡下さい

私達は、グローバルに活躍する経営者が抱える最重要経営課題に対して、厳しい競争環境の中でも成長し続け、「結果」を出すために支援しています。